Code intelligence

FDA-BLA761183 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-BLA761183.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: TZIELD (TEPLIZUMAB-MZWV) — Type 1 - New Molecular Entity

Policy FDA-BLA761183 · Oncology

Critical

With the approval of TZIELD (teplizumab-mzwv) as an injectable, it is expected to receive a J-code assignment for Medicare billing under Part B. A payment model of ASP + 6% may be applicable, and give

View alert